Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

* Definitions:

* Platinum-free interval (PFI) is the period of time from the date of last platinum therapy to the date of progression (recurrence by CA-125, CT, etc.; CT is preferred) of disease or initiation of subsequent therapy (whichever occurs first); non-platinum maintenance therapy (e.g., extending taxane treatment) is excluded as a ?subsequent therapy;? if the patient?s last regimen used platinum, and she has NOT progressed before enrolling onto this study, then her PFI will be calculated from the date of last platinum therapy to the date of registration onto this study

* PFI for the most recent platinum therapy will need to be calculated before enrollment onto this study for stratification purposes (i.e. balanced randomization)

* Patients who have a PFI =\< 182 days (26 weeks) are defined as ?platinum resistant;? patients who have 182 \< PFI =\< 365 days are defined as ?GOG platinum sensitive;? finally, patients with PFI \> 365 days are defined as ?platinum sensitive?

ANC greater than or equal to 1,500/mcl

Platelets greater than or equal to 100,000/mcl

Hemoglobin greater than or equal to 9 g/dL

Creatinine less than or equal to 1.5 x institutional upper limit of normal (ULN)

Potassium within the normal reference range for the laboratory; correction with supplements is acceptable

Magnesium within the normal reference range for the laboratory; correction with supplements is acceptable

Calcium within the normal reference range for the laboratory; correction with supplements is acceptable

Bilirubin less than or equal to 1.5 x ULN

Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\]) =\< less than or equal to 3 x ULN

Alkaline phosphatase less than or equal to 2.5 x ULN

Prothrombin time (PT) such that international normalized ratio (INR) is less than or equal to 1.5 x ULN (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin) and a partial thromboplastin time (PTT) less than or equal to 1.5 x ULN

Urine protein should be screened by urine analysis; if protein is 2+ or higher, a 24-hour urine protein should be obtained and the level must be \< 1,000 mg (\< 1.0 g/24 hrs) for patient enrollment

Patients of childbearing potential must have a negative serum pregnancy test prior to the study entry and be practicing an effective form of contraception

Patients must have signed an approved informed consent and authorization permitting the release of personal health information

Patients must meet pre-entry requirements

Patients who have received prior fosbretabulin tromethamine or any other vascular disrupting agent (VDA)

Patients with other invasive malignancies, with the exception of non-melanoma skin cancer and other specific malignancies as noted below, are excluded if there is any evidence of other malignancy being present within the last three years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy

Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for the treatment of ovarian, fallopian tube or primary peritoneal cancer within the last three years are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease

Patients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER THAN for the treatment of ovarian, fallopian tube or primary peritoneal cancer within the last three years are excluded; patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease

Patients with serious non-healing wound, ulcer, or bone fracture; this includes history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 90 days prior to the first date of study treatment

Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels

Patients with history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months prior to the first date of treatment on this study

Patients with clinically significant cardiovascular disease; this includes:

* Uncontrolled hypertension, defined as systolic \> 150 mm Hg or diastolic \> 90 mm Hg despite antihypertensive medications

* History of torsade de pointes, ventricular tachycardia or fibrillation, pathologic sinus bradycardia (\< 60 beats per minute \[bpm\]), heart block (excluding 1st degree block being, PR interval prolongation only), congenital long QT syndrome, new ST segment elevation or depression, or new Q waves on electrocardiogram (ECG)

* Patients with corrected QT interval (QTc) \> 470 msec

* Requirement for receiving any drug known to prolong the QTc interval, including anti-arrhythmic medications; stable regimen of antidepressants of the selective serotonin reuptake inhibitor (SSRI) class is allowed

* Myocardial infarction or unstable angina within 6 months prior to registration

* New York Heart Association (NYHA) class II or greater congestive heart failure

* Serious cardiac arrhythmia requiring medication; this does not include asymptomatic, atrial fibrillation with controlled ventricular rate

* Patients who have received prior treatment with an anthracycline (including doxorubicin and or pegylated liposomal doxorubicin \[Doxil; PLD\]) must have an echocardiogram assessment and are excluded if they have an ejection fraction \< 50%

* Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or greater peripheral vascular disease (at least brief \[\< 24 hrs\] episodes of ischemia managed non-surgically and without permanent deficit)

Known hypersensitivity to any of the components of fosbretabulin tromethamine or bevacizumab

Major surgery within 28 days prior to the first date of study treatment

Anticipation of need for major surgical procedures during the course of the study

Core biopsy within 7 days prior to the first date of study treatment

Patients with clinical symptoms or signs of gastrointestinal obstruction and patients who require parenteral hydration and/or nutrition; patients with bowel involvement on CT scan

Patients with medical history or conditions not otherwise previously specified which in the opinion of the investigator should exclude participation in this study; the investigator can consult the Study Chair or Study Co-Chairs for uncertainty in this regard

Patients who are pregnant or nursing

What this study is about